415 results about "Lungs tissues" patented technology

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention provides a dynamic lung compliance monitoring method based on electrical impedance tomography, and the method comprises the steps: obtaining an electrical impedance signal and pressure-volume curve data, recording a time sequence signal of lung tissue in a dynamic ventilation process through a synchronous collection device, and obtaining an original multi-dimensional data set; aiming at the second feature set, eliminating redundant parameters by applying a feature screening mechanism, and evaluating the importance of each feature in different breathing stages through an information gain algorithm to obtain a third feature set; constructing a dynamic compliance monitoring model through the weighted feature set, and fitting a lung compliance change trend by using a support vector regression algorithm to obtain a real-time prediction result; and according to the updated prediction result, evaluating the improvement degree of the calculation efficiency, and judging whether the real-time performance meets clinical requirements or not by recording the model operation time and the resource occupancy rate so as to obtain final monitoring output.

The invention discloses a biologically safe and degradable cerium-based tannic acid nano-enzyme as well as a preparation method and application thereof. The nano-enzyme can be administrated through a non-invasive nasal cavity. In an area with excessive ROS, thioketone on CeTA-k1tkP is destroyed, PEG is removed, hydrogen bonds of an amino acid sequence are allowed to form beta-sheet, the beta-sheet is accumulated at an inflammation part, and a fiber or network structure is formed. Meanwhile, CeTA-k1tkP shows enzyme-like capacity, ROS is effectively eliminated, inflammation is effectively relieved, and systemic immunosuppression is avoided at the same time. In an influenza A (Flu A) virus or Sendai virus (SeV) mediated viral pneumonia model, CeTA-k1tkP can generate responsive deformation in inflammatory lung tissues, so that the nano-enzyme effectively decomposes ROS (reactive oxygen species). In addition, the CeTA-k1tkP can relieve bacterial inflammation and reduce tissue damage in a mouse viral pneumonia model with secondary bacterial infection.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses an application of osmundone in preparation of a medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia. Experimental results of an MRSA mouse pneumonia infection model show that osmundone can significantly reduce the bacterial load in lung tissues, alleviate excessive inflammatory response caused by infection and effectively improve the survival rate of mice. In addition, the invention discloses that osmundone reduces the adhesion and invasion ability of bacteria, reduces the toxicity of the bacteria and plays an antibacterial role by inhibiting the protein activity of staphylococcus aureus Sortase A (SrtA). Different from traditional antibiotics, osmundone does not apply survival pressure to bacteria, so that generation of drug resistance is not easily induced. On the basis, osmundone shows a good application prospect in the aspect of research and development of safe and effective MRSA infectious pneumonia treatment drugs.

The invention relates to the technical field of medical image processing, in particular to a pulmonary blood vessel perfusion analysis method based on drainage basin dynamics, which comprises the following steps: acquiring a pulmonary artery blood vessel tree and a pulmonary artery CT film; extracting the pulmonary artery blood vessel tree based on the pulmonary artery blood vessel tree and the pulmonary artery CT film; based on the pulmonary artery blood vessel tree, pressure gradient fields in the pulmonary artery blood vessel tree and on the wall of the pulmonary artery blood vessel tree are calculated; extracting a pulmonary vein basin based on the pressure gradient field; based on the pulmonary vein drainage basin, perfusion analysis is achieved in combination with dynamic hemodynamic simulation; on the basis of perfusion analysis results, lung tissue blood supply conditions are evaluated, a multi-stage connected domain detection method is adopted, the method can more accurately extract a complex pulmonary artery blood vessel tree structure, the actual distribution condition of blood flow can be more truly reflected on the basis of a pressure gradient field drainage basin division method, and dynamic blood flow simulation is introduced, so that the dynamic blood flow simulation effect is improved. By means of the method, perfusion changes in the breathing process can be comprehensively captured, and more comprehensive diagnosis information is provided.

The invention discloses a leuconostoc mesenteroides substrain, the preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.30904, the preservation date is June 7, 2024, the preservation classification is named as leuconostoc mesenteroides, and the preservation unit is the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The strain provided by the invention is harmless to animals, and has the remarkable effects of relieving lung tissue inflammatory infiltration caused by bronchial asthma, reducing release of serum IgE and Th2 type cell factors, inhibiting excessive lung macrophage replacement activation and improving allergic airway inflammation.

The invention relates to the field of medicine and tissue engineering, more specifically to means and methods to boost the repair of epithelial cells, such as damaged lung tissue as is observed in diseases with defective lung repair including as chronic obstructive pulmonary disease (COPD). Provided is osteoglycin (OGN; Osteoinductive factor, mimecan), or a functional fragment thereof, for use as an agent to promote the regeneration of epithelial cells or epithelial tissue.

The invention belongs to the field of pharmacy, and relates to a medicine for treating pulmonary fibrosis, in particular to application of an anti-Gremlin1 antibody to preparation of a medicine for preventing and treating pulmonary fibrosis. The Gremlin1 antibody disclosed by the invention can be applied to prevention and treatment of pulmonary fibrosis, effectively improves bleomycin (BLM)-induced pulmonary fibrosis lesions of mice and improves the survival rate of the mice. Compared with a BLM group, the mouse inspiration capacity (IC) and the lung static compliance (CRS) treated by the Gremlin1 antibody are remarkably improved, the hydroxyproline content in lung tissue is remarkably reduced, and compared with the BLM group, the Ashcroft score, the collagen deposition area in Masson three-color dyeing and the Sirius red dyeing area of an antibody intervention group are remarkably reduced, and the proportion of activated endothelial cells and the proportion of transition-state epithelial cells are remarkably reduced. Therefore, the Gremlin1 antibody can be used for preparing the medicine for preventing and / or treating the pulmonary fibrosis.

The invention discloses a method for treating chicken chronic respiratory diseases by using MG-sEV-miRNA-200, and belongs to the technical field of exosomes, and the method comprises the following steps: step 1, constructing an MG infected cell model, and carrying out fluorescence quantitative analysis on gga-miR-200a-3p in cells / exosomes in different time periods of infection; step 2, carrying out overexpression on the miR-200 in the ACE II cells, and extracting an exosome (MG-sEV-miRNA-200) rich in the miR-200; step 3, constructing a cell model for exosome treatment, and carrying out RNA-seq sequencing to identify an exosome treatment target and a pathway rich in gga-miR-200a-3p; step 4, constructing a chick embryo model infected by MG, and injecting MG-sEV-miRNA-200 to intervene in respiratory diseases caused by MG; 5, evaluating the curative effect; mG-sEV is taken as a medium, miRNA can be protected from being influenced by RNA enzyme activity, the gga-miR-200a-3p-rich MG-sEV has the advantages of low immunogenicity, low cytotoxicity, relatively high stability, relatively high biocompatibility and the like, and the MG-sEV rich in gga-miR-200a-3p can be used for remarkably relieving lung inflammation injury caused by MG infection and reducing the bacterium carrying amount of MG in lung tissues; the method has a wide application prospect in the treatment of chicken chronic respiratory diseases.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention discloses a mycobacterium tuberculosis tandem DNA vaccine W543 as well as a preparation method and application thereof. The DNA vaccine W543 provided by the invention is a novel mycobacterium tuberculosis DNA vaccine with multiple antigen immunodominance epitopes, which is constructed by connecting polypeptides or epitope coding genes of a mycobacterium tuberculosis proliferation period antigen and a latent related antigen in series through a linker by virtue of genetic engineering and inserting the polypeptides or epitope coding genes into an eukaryotic expression vector pVAX1. Experiments prove that the mycobacterium tuberculosis specific tandem DNA vaccine W543 disclosed by the invention is used as an immunomodulatory preparation, mainly stimulates immune response of Th1 type, and can significantly enhance the specific cellular immune function of mice; as a preventive treatment preparation, the bacterial count of lung and liver tissues can be reduced, the lesion range of the lung tissues is remarkably reduced, the lesion is relieved, and the treatment effect is slightly superior to that of an existing commercial tuberculosis latent infection prevention and treatment preparation, namely, microkalidium vaccine.

The invention provides an eucheuma compound for improving lung function and a preparation method thereof. The eucheuma compound is prepared from the following raw materials in parts by weight: 25 to 35 parts of eucheuma extract, 13 to 17 parts of oyster peptide, 8 to 12 parts of fish collagen peptide, 4 to 6 parts of rhizoma polygonati, 3 to 5 parts of herba cistanche, 2 to 4 parts of semen euryales and 1 to 2 parts of longan. Secondly, the eucheuma extract rich in eucheuma polysaccharide, eucheuma polypeptide and the like is prepared through the technology. The components in the formula of the eucheuma compound have a synergistic effect, and the prepared eucheuma compound can effectively control the lung coefficient and increase of the hydroxyproline content in lung tissue and improve inflammatory infiltration and fibrohyperplasia of the lung. In addition, the compound also inhibits oxidative stress reaction and further inhibits pulmonary fibrosis; the lung lesion is effectively inhibited, the lung function is improved, and the lung health is promoted.

The invention discloses an application of a THBS1 inhibitor in preparation of a medicine for preventing or treating lung tissue inflammation induced by novel coronavirus, and provides a related medicine, application and a method, the THBS1 gene inhibitor or a TSP-1 protein inhibitor is used for treating the lung tissue inflammation infected by SARS-CoV-2, the effect is remarkable, and the medicine can be used for preparing medicines for preventing or treating the lung tissue inflammation induced by the novel coronavirus. The SARS-CoV-2 gene is a novel target for treating severe pneumonia caused by SARS-CoV-2 infection.

The invention relates to the technical field of immunotherapy, in particular to a regulatory protein recombinant vaccine and application thereof in pulmonary fibrosis treatment. The vaccine contains polypeptide of amphiregulin antigen epitopes, and the amino acid sequence of the vaccine is shown as SEQ ID No. 1. A research result shows that the recombinant vaccine can effectively induce generation of a specific antibody aiming at the AREG protein in a mouse body, so that secretion of the AREG protein and activation of downstream receptors of the AREG protein in the pulmonary fibrosis process are inhibited. By reducing collagen deposition in lung tissue and reducing tissue structure damage, the recombinant vaccine significantly reduces gene expression of fibrosis-related protein, recovers lung functions of pulmonary fibrosis model mice, and inhibits further development of diseases. In addition, the recombinant vaccine can be administered in an aerosol inhalation mode, and has broad-spectrum, efficient and long-term stable expression and good safety. The invention provides a brand-new targeted therapy means for clinical prevention and treatment of pulmonary fibrosis, and shows a wide application prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The present invention belongs to the technical field of antiviral microecological preparations for livestock and poultry, and specifically relates to Bacillus amyloliquefaciens H-6 and its application in the preparation of a medicament for treating or preventing porcine reproductive and respiratory syndrome virus (PRRSV) infection. The preservation number of the said Bacillus amyloliquefaciens is CCTCC NO: M 20242740. This strain can reduce the infection activity of PRRSV cells, inhibit the invasion and infection of PRRSV to cells, and reduce the proliferation of the virus on cells. The anti-infection research at the cell level and the animal body level shows that this strain has a significant anti-PRRSV effect both in vivo and in vitro, can reduce the proliferation of the virus in pigs, reduce the damage of PRRSV infection to lung tissues and organs, effectively control the adverse effects caused by PRRSV infection to the body, and can weaken the clinical symptoms of pigs during PRRSV infection, and can be used for preventing and controlling the occurrence of porcine reproductive and respiratory syndrome.

The invention belongs to the technical field of application of plant exosomes, and discloses a plant-derived hybrid exosome and application of the plant-derived hybrid exosome in pulmonary fibrosis resistance. After screening a proper proportion, the obtained hybrid exosome has an obvious treatment effect on a mouse with pulmonary fibrosis induced by bleomycin, and the treatment effect is specifically shown as follows: (1) the hybrid exosome can obviously relieve lung inflammatory cell infiltration of the model mouse, protect a pulmonary alveolar structure and relieve the degree of pulmonary fibrosis; (2) the hybrid exosome can effectively reduce the expression levels of TNF-alpha, IL-1beta and IL-6, and can effectively slow down the pulmonary fibrosis process; the lung tissue inflammation is inhibited; and (3) the hybridized exosome inhibits the generation of ECM (extracellular matrix) and inhibits epithelial mesenchymal transition, so that the anti-fibrosis effect is achieved. The plant source hybrid exosome prepared by the invention is wide in plant source, simple in exosome preparation process and low in cost, and provides new possibility for treating pulmonary fibrosis.

The invention provides a non-small cell lung cancer biomarker and application thereof, and particularly relates to application of a reagent for detecting snoRNA SNORD78 or a fragment thereof in preparation of a kit, and the kit is used for diagnosing non-small cell lung cancer and / or screening non-small cell lung cancer tissues. Samples obtained from healthy paracancerous lung tissues and non-small cell lung cancer patients in different staging stages are screened, analyzed and verified to find that snoRNA SNORD78 or fragments thereof have significant expression difference in healthy lung tissue samples (paracancerous) and non-small cell lung cancer tissue samples; moreover, obvious expression difference also exists in healthy individual tissues of the non-small cell lung cancer and individual tissues of different stages of the non-small cell lung cancer, a new molecular marker is provided for indicating the non-small cell lung cancer and the disease course development thereof, and a new thought is provided for preventing and / or treating the non-small cell lung cancer.

A method for rapidly and efficiently inducing multiple human airway epithelium in vitro models for a long time relates to the technical field of organoid culture.The method comprises the steps that firstly, a clinical lung tissue sample is induced and differentiated to form a cilia inward lung airway organoid, the cilia inward lung airway organoid is digested into single cells, and multiplication culture is conducted through a basal cell culture medium; the obtained basal cells are subjected to induced differentiation to form cilia outward lung airway organs and a gas-liquid interface culture model. The two types of models can successfully simulate the functional cellular morphology of the human airway epithelium in vitro, can be used as experimental models for disease modeling, drug screening, toxicity testing and the like, and can simulate biological models of the human airway structure and function. The method can solve the problems that clinical samples are difficult to obtain and primary lung epithelial cells have limited passage times in the construction process of lung airway organs, and realizes long-term rapid and efficient induction of various human airway epithelium in-vitro models.

The invention discloses application of CREB3L1 in diagnosis and treatment of systemic sclerosis, and belongs to the technical field of biological medicine. The invention discovers that CREB3L1 has the function of regulating and controlling fibrosis of skin and lung tissues of a patient with systemic sclerosis for the first time, and plays an important role in the progress of fibrosis of systemic sclerosis. The CREB3L1 can be used as a biomarker for diagnosis and auxiliary diagnosis of systemic sclerosis, and the CREB3L1 inhibitor can be used as an effective component for controlling and / or reversing fibrosis of systemic sclerosis, and has a good clinical application prospect. A new target is provided for diagnosis and treatment of systemic sclerosis, and a solid research foundation is laid for development of drugs for resisting systemic sclerosis fibrosis.

The invention belongs to the technical field of organoid culture, and particularly relates to a pulmonary alveolar organoid with an endogenous vascular network and a construction method of the pulmonary alveolar organoid. Aiming at the problems that mesoderm and endoderm are difficult to induce at the same time, the operation process is long, the difficulty is high and the like when a vascularized alveolar organ is constructed by an existing method, the invention provides the construction method of the alveolar organ with the endogenous vascular network. The method comprises the following steps: simultaneously and directionally inducing and differentiating human induced pluripotent stem cells (hiPSC) into fixed endoderm and mesoderm, anterior intestine endoderm, abdominal side anterior intestine endoderm and lung progenitor cells by adopting a one-step method, and promoting endothelial cell proliferation in an endogenous induced differentiation process through a specific growth factor combination. A functional vascular network is formed; and vascularized alveolar organs are induced to be generated. According to the invention, a qi-blood barrier structure in which vascular endothelial cells and pulmonary epithelial cells are tightly connected is successfully reproduced, the gas exchange function of lung tissues can be simulated, and a new way is provided for construction of vascularized alveolar organs.

The invention belongs to the technical field of biological pharmacy, and discloses application of Danthron in preparation of a medicine for preventing or treating pulmonary fibrosis. The Danthron inhibits the fibroblasts from differentiating to myofibroblasts by reducing the transcriptional level and protein expression level of fibronectin, alpha-actin and I-type collagen in the fibroblasts in lung tissues, so that the pulmonary fibrosis process is slowed down, and a new treatment strategy is provided for pulmonary fibrosis.

The invention discloses a formyl peptide receptor 1 polypeptide blocker for resisting acute lung injury and pharmaceutical application thereof. The invention provides a polypeptide with a sequence as shown in Sequence NO.1, and the polypeptide is reported for the first time. Pharmacological activity studies show that the polypeptide shown as Sequence NO.1 can significantly improve lung tissue structure damage of acute lung injury model mice, reduce the level of proinflammatory factors and reduce neutrophil infiltration, and shows an obvious acute lung injury resisting effect. Therefore, the polypeptide as shown in the Sequence NO.1 provided by the invention has a prospect of being developed into the acute lung injury resisting medicine. Specifically, the polypeptide shown as Sequence NO.1 can be used as a unique active ingredient for preparing the medicine for treating and resisting the acute lung injury, and can also be combined with other active ingredients to form a composition for preparing the medicine for treating and resisting the acute lung injury.

Application of a high-purity inonotus obliquus polysaccharide component belongs to the technical field of biological medicine, and the high-purity inonotus obliquus polysaccharide component plays a role in preventing and treating by inhibiting autophagy of lung tissue cells and depending on an lncRNA Rmst pathway, and can reduce the number of autophagosomes in lung tissues and the level of conversion from LC3-I to LC3-II; according to the method, the sugar content of IOP can be remarkably increased compared with crude polysaccharide, the protein content is remarkably reduced, four active components with specific molecular weights are obtained through separation, the molecular weight ranges are definite (IOP-g1gt, IOP-g2gt, IOP-g3gt and IOP-g4), and the requirements of medicine research and development for controllable purity and definite components are met.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

Methods and systems are described for a high-level approach to organ generation by self-assembly using bioprinting, overcoming longstanding challenges in replicating the intricate architecture and function of complex organs. In some embodiments, these methods are used to produce lung tissues and microtissues, demonstrating how mini-lung constructs can be produced on a small scale through specialized processes and media. In such embodiments, methods and systems for generating bioprinted lung tissues and microtissues are provided, as are tissues made by such methods. The tissues find use in implantation, drug discovery, personalized medicine, and other applications. Methods for the large-scale manufacturing of lung epithelial stem cells are also provided.

The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) NO.30979, the preservation date is June 17, 2024, the preservation classification is named as Lactobacillus brevis, and the preservation unit is the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The strain is harmless to animals and has the remarkable effects of relieving lung tissue inflammatory infiltration caused by bronchial asthma, reducing release of serum IgE and Th2 type cell factors, inhibiting activation of an NF-kappa B channel and improving allergic airway inflammation. The invention also discloses application of the strain and the thallus component thereof in preparation of drugs for preventing and treating allergic asthma.